Followers | 11 |
Posts | 1455 |
Boards Moderated | 0 |
Alias Born | 02/01/2013 |
Wednesday, November 18, 2015 9:14:49 AM
"Organovo is proud to be named a top health innovator for this year by Popular Science, a leading science and technology magazine,” said Keith Murphy, chairman and chief executive officer of Organovo. “The past year has been important for us as we successfully launched our exVive3DTM Human Liver Tissue and continue to grow the market for bioprinted tissues in drug research and development. We’re excited to advance our next portfolio offering of 3D human kidney tissue.”
“The Best of What’s New awards honor the innovations that surprise and amaze us—those that challenge our view of what’s possible in the future,” said Cliff Ransom, Editor-in-Chief of Popular Science. “The award is Popular Science’s top prize, and the 100 winners—chosen from among thousands of nominees—are each a revolution in their respective fields.”
Organovo's 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. The Company is building a number of 3D tissue models for research and drug discovery applications, as well as working to fulfill their vision of building human tissues for surgical therapy and transplantation. Organovo is also on track to bring its 3D bioprinted human kidney tissue to the broader commercial market in 2016 for use in toxicology and other preclinical drug testing.
The Company has announced collaborations with L’Oreal to develop 3D printed skin tissue for product evaluation and other areas of advanced research, with Merck to develop multiple custom tissue models for drug development, and with the Yale School of Medicine to develop 3D organ tissues for surgical transplantation research.
Recent ONVO News
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/09/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:05:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2023 11:05:02 AM
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results • GlobeNewswire Inc. • 12/06/2023 01:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/01/2023 09:07:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:41:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:40:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:34:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:32:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/15/2023 09:41:04 PM
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/13/2023 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:10:34 PM
- Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/08/2023 01:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 12:05:08 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/22/2023 08:05:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2023 09:06:56 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM